Full Press Release Details
Eidos Therapeutics Reports Second Quarter 2018 Financial Results And Provides Corporate Update.
BBIO
Eidos Therapeutics Reports Second Quarter 2018 Financial Results And Provides Corporate Update
Key Takeaway: Eidos Therapeutics Reports Second Quarter 2018 Financial Results And Provides Corporate Update
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis